Literature DB >> 25283071

Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.

Wen-Jian Qian1, Jung-Eun Park, Dan Lim, Christopher C Lai, James A Kelley, Suk-Youl Park, Ki Won Lee, Michael B Yaffe, Kyung S Lee, Terrence R Burke.   

Abstract

Binding of polo-like kinase 1 (Plk1) polo-box domains (PBDs) to phosphothreonine (pThr)/phosphoserine (pSer)-containing sequences is critical for the proper function of Plk1. Although high-affinity synthetic pThr-containing peptides provide starting points for developing PBD-directed inhibitors, to date the efficacy of such peptides in whole cell assays has been poor. This potentially reflects limited cell membrane permeability arising, in part, from the di-anionic nature of the phosphoryl group or its mimetics. In our current article we report the unanticipated on-resin N(τ)-alkylation of histidine residues already bearing a N(π)- alkyl group. This resulted in cationic imidazolium-containing pThr peptides, several of which exhibit single-digit nanomolar PBD-binding affinities in extracellular assays and improved antimitotic efficacies in intact cells. We enhanced the cellular efficacies of these peptides further by applying bio-reversible pivaloyloxymethyl (POM) phosphoryl protection. New structural insights presented in our current study, including the potential utility of intramolecular charge masking, may be useful for the further development of PBD-binding peptides and peptide mimetics.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Plk1; cationic dialkyl histidine; crystal structure; intramolecular charge masking; phosphopeptides; polo kinase; polo-box domain

Mesh:

Substances:

Year:  2014        PMID: 25283071      PMCID: PMC4895914          DOI: 10.1002/bip.22569

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  50 in total

Review 1.  Prodrugs of biologically active phosphate esters.

Authors:  Carsten Schultz
Journal:  Bioorg Med Chem       Date:  2003-03-20       Impact factor: 3.641

2.  Plaque production by the polyoma virus.

Authors:  R DULBECCO; G FREEMAN
Journal:  Virology       Date:  1959-07       Impact factor: 3.616

Review 3.  Polo-like kinases, an introduction.

Authors:  Wei Dai
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

Review 4.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

5.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Authors:  Kiranmai Gumireddy; M V Ramana Reddy; Stephen C Cosenza; R Boominathan; R Boomi Nathan; Stacey J Baker; Nabisa Papathi; Jiandong Jiang; James Holland; E Premkumar Reddy
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

6.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

7.  Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates.

Authors:  Andrew E H Elia; Lewis C Cantley; Michael B Yaffe
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

8.  The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex.

Authors:  Kin-Yip Cheng; Edward D Lowe; John Sinclair; Erich A Nigg; Louise N Johnson
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

9.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.

Authors:  Sang-Moon Yun; Tinoush Moulaei; Dan Lim; Jeong K Bang; Jung-Eun Park; Shilpa R Shenoy; Fa Liu; Young H Kang; Chenzhong Liao; Nak-Kyun Soung; Sunhee Lee; Do-Young Yoon; Yoongho Lim; Dong-Hee Lee; Akira Otaka; Ettore Appella; James B McMahon; Marc C Nicklaus; Terrence R Burke; Michael B Yaffe; Alexander Wlodawer; Kyung S Lee
Journal:  Nat Struct Mol Biol       Date:  2009-07-13       Impact factor: 15.369

10.  Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1.

Authors:  Fa Liu; Jung-Eun Park; Wen-Jian Qian; Dan Lim; Andrej Scharow; Thorsten Berg; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Chembiochem       Date:  2012-05-08       Impact factor: 3.164

View more
  15 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.

Authors:  Jung-Eun Park; Tae-Sung Kim; Bo Yeon Kim; Kyung S Lee
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.

Authors:  Karine Normandin; Jean-François Lavallée; Marie Futter; Alexandre Beautrait; Jean Duchaine; Sébastien Guiral; Anne Marinier; Vincent Archambault
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

4.  Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.

Authors:  Xue Zhi Zhao; David Hymel; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2017-02-28       Impact factor: 3.641

5.  Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.

Authors:  Vincent Archambault; Karine Normandin
Journal:  Cell Cycle       Date:  2017-05-19       Impact factor: 4.534

6.  Mitsunobu mischief: neighbor-directed histidine N(τ)-alkylation provides access to peptides containing selectively functionalized imidazolium heterocycles.

Authors:  Wen-Jian Qian; Terrence R Burke
Journal:  Org Biomol Chem       Date:  2015-03-05       Impact factor: 3.876

7.  Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.

Authors:  David Hymel; Robert A Grant; Kohei Tsuji; Michael B Yaffe; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2018-08-19       Impact factor: 2.823

8.  Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.

Authors:  David Hymel; Terrence R Burke
Journal:  ChemMedChem       Date:  2017-01-09       Impact factor: 3.466

9.  Neighbor-directed histidine N (τ)-alkylation: A route to imidazolium-containing phosphopeptide macrocycles.

Authors:  Wen-Jian Qian; Jung-Eun Park; Robert Grant; Christopher C Lai; James A Kelley; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Biopolymers       Date:  2015-11       Impact factor: 2.505

10.  Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models.

Authors:  Pethaiah Gunasekaran; Min Su Yim; Mija Ahn; Nak-Kyun Soung; Jung-Eun Park; Jaehi Kim; Geul Bang; Sang Chul Shin; Joonhyeok Choi; Minkyoung Kim; Hak Nam Kim; Young-Ho Lee; Young-Ho Chung; Kyeong Lee; Eunice EunKyeong Kim; Young-Ho Jeon; Min Ju Kim; Kyeong-Ryoon Lee; Bo-Yeon Kim; Kyung S Lee; Eun Kyoung Ryu; Jeong Kyu Bang
Journal:  J Med Chem       Date:  2020-11-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.